Effects of Liraglutide on Weight Loss, Fat Distribution, and β-Cell Function in Obese Subjects With Prediabetes or Early Type 2 Diabetes - Santilli, Francesca; Simeone, Paola G.; Guagnano, Maria T.; Leo, Marika; Maccarone, Marica T.; Di Castelnuovo, Augusto; Sborgia, Cristina; Bonadonna, Riccardo C.; Angelucci, Ermanno; Federico, Virginia; Cianfarani, Stefano; Manzoli, Lamberto; et al. (Diabetes care, 2017)
Keywords: Adipocytes - drug effects; Blood Glucose - metabolism; Body Mass Index; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Female; Glucagon-Like Peptide 1 - analogs & derivatives; Glucagon-Like Peptide 1 - therapeutic use; Glucose Tolerance Test; Glycated Hemoglobin A - metabolism; Humans; Hypoglycemic Agents - therapeutic use; Insulin-Like Growth Factor I - metabolism; Insulin-Like Growth Factor II - metabolism; Insulin-Secreting Cells - drug effects; Insulin-Secreting Cells - metabolism; Life Style; Liraglutide - therapeutic use; Longitudinal Studies; Lost to Follow-Up; Male; Metformin - therapeutic use; Middle Aged; Obesity - blood; Obesity - complications; Obesity - drug therapy; Prediabetic State - blood; Prediabetic State - drug therapy; Risk Factors; Weight Loss - drug effects